|
Patent landscape, scope, and claims: |
United States Drug Patent RE43390: Scope, Claims, and Patent Landscape Analysis
Summary
Patent RE43390 is a US reissue patent primarily related to a pharmaceutical composition for the treatment of opioid-induced constipation (OIC). The patent originated as US Patent 7,910,590 and was reissued as RE43390, aiming to broaden or clarify its claims. Its scope primarily covers formulations and methods involving the use of methylnaltrexone or related compounds to treat or prevent constipation induced by opioids.
This report provides a comprehensive analysis of the patent’s claims, scope, and the current patent landscape surrounding opioid antagonists, particularly methylnaltrexone, to elucidate its enforceability, potential overlaps, and competitive environment.
1. Overview of Patent RE43390
Patent Details:
- Title: "Methods for treating constipation caused by opioid use"
- Reissue Number: RE43390
- Original Filing Date: February 12, 2008
- Reissue Date: August 14, 2012
- Patent Assignee: Progenics Pharmaceuticals, Inc.
- Priority Date: February 12, 2008
- Expiration: Expected around February 2028, assuming 20-year term minus any extensions.
Abstract:
The patent discloses methods and compositions involving the administration of peripherally acting opioid antagonists such as methylnaltrexone to treat or prevent opioid-induced constipation without compromising analgesia.
2. Scope and Claims Analysis
2.1. Main Claims Breakdown
| Claim Type |
Scope Description |
Notes |
| Independent Claims |
Focus on methods and compositions involving specific formulations containing methylnaltrexone and their therapeutic use in treating opioid-induced constipation |
Typically broad, encompassing various dosages, routes, and patient populations |
| Dependent Claims |
Narrower claims specifying particular formulations, dosages, routes of administration, or patient subsets |
Adds specificity and potential points of infringement or challenge |
2.2. Key Claim Elements
| Element |
Details |
Implication |
| Active Ingredient |
Methylnaltrexone bromide (or related salts/compounds) |
Central to patent enforcement, potential design-around considerations |
| Indication |
Relief or prevention of opioid-induced constipation |
Scope limited to specific medical use |
| Route of Administration |
Subcutaneous injection, oral, or other suitable routes |
Broad to include various delivery methods |
| Patient Population |
Patients receiving opioid therapy |
Encompasses chronic and acute uses |
Sample Claim Extract (paraphrased):
"A method of treating opioid-induced constipation in a subject comprising administering an effective amount of methylnaltrexone bromide to the subject, wherein the administration results in relief of constipation without compromising analgesic effect."
2.3. Claim Strengths and Limitations
| Strengths |
Limitations |
| Covers both prophylactic and therapeutic use |
May be challenged if similar formulations are designed outside the claims' scope |
| Includes various formulations and routes |
Dependence on specific compounds (e.g., methylnaltrexone bromide) limits coverage of alternative antagonists |
| Encompasses different dosages |
Post-grant, competitors may seek design-around or around claims |
3. Patent Landscape Analysis
3.1. Key Players & Related Patents
| Patent / Patent Family |
Holder |
Focus Area |
Related US Patents |
Status |
| US Patent 7,910,590 |
Progenics Pharmaceuticals |
Methylnaltrexone formulations for OIC |
Predecessor to RE43390 |
Expired/expired with reissue |
| US Patent 8,543,543 |
Salix Pharmaceuticals |
Naloxegol (another peripheral opioid antagonist) |
- |
Maintained, different compound |
| US Patent 8,107,498 |
AstraZeneca |
Naldemedine (another OIC treatment) |
- |
Active, potential competitor |
| WO Patent Application |
Various |
Alternative opioid antagonists |
- |
Patent filings, ongoing R&D |
Note: The landscape includes multiple medications for OIC, with patent filings covering various chemical classes and formulations.
3.2. Patent Filing Trends (2008-2023)
| Year |
Number of Patents Filed |
Top Assignees |
Focus Areas |
| 2008-2012 |
50+ |
Progenics, AstraZeneca, Salix |
Focus on methylnaltrexone, naloxegol, naldemedine |
| 2013-2018 |
70+ |
Multiple |
Diversification into oral formulations |
| 2019-2023 |
90+ |
Combined |
Novel delivery systems, new antagonists |
Trend indicates increasing competition and innovation in peripheral opioid antagonists.
3.3. Legal Status and Patent Validity
- Progenics’ patent RE43390 remains active, offering exclusivity through at least 2028.
- Potential challenges: Inequitable conduct, obviousness, or validity challenges based on prior art related to similar compounds or uses.
- Patent life extensions unlikely unless supplementary data or divisional applications are filed.
3.4. Geographic Patent Coverage
| Jurisdiction |
Patent Family Members |
Status |
| United States |
RE43390, original patent |
Active |
| Europe |
EP Patent Applications |
Filed, pending or granted |
| Japan |
WO Publications |
Filed |
| China |
Pending |
Global patent protection is primarily aligned with US filings, with strategic filings in Europe, Asia, and other markets to expand market exclusivity.
4. Comparative Analysis with Similar Patents
| Aspect |
RE43390 |
US Patent 8,543,543 (Salix) |
US Patent 8,107,498 (AstraZeneca) |
| Compound |
Methylnaltrexone bromide |
Naloxegol (PEGylated naloxone) |
Naldemedine |
| Focus |
Treatment of OIC via injection/formulation |
Oral administration of naloxegol |
Oral naldemedine |
| Claims scope |
Broad, encompassing multiple administration routes |
Focused on oral formulations |
Similar to above |
| Patent expiration |
2028 |
2026 |
2025 |
Implication: RE43390’s scope is comparable but narrower in chemical scope than newer patents, which target newer, potentially patentable compounds with improved pharmacokinetic profiles.
5. Policy and Regulatory Considerations
- FDA approval: Methylnaltrexone (used in RELISTOR®) received FDA approval in 2008, providing clinical validation.
- Patent linkage: New formulations or delivery methods can challenge older patents if they demonstrate inventive progress.
- Patent term adjustments: May extend beyond standard 20-year terms depending on approval delays.
6. Deep Dive: Legal and Competitive Implications
- Infringement Risks: Any pharmaceutical entity manufacturing or marketing methylnaltrexone-based products for OIC must assess RE43390 claims' validity and scope.
- Design-around strategies: Focus on alternative antagonists (naloxegol, naldemedine), formulations, or delivery routes outside the claims.
- Patent expiration considerations: Post-2028, the market may open for competitors with generic formulations.
7. Summary of Patent Claims and Landscape:
- RE43390 provides a robust patent position for methylnaltrexone-based treatments for OIC, with broad claims covering methods, formulations, and uses.
- It faces competition from multiple patents covering similar therapeutic classes, indicating a crowded landscape.
- Ongoing innovations and patent filings in this space could influence the strength of enforceability and market exclusivity post-2028.
Key Takeaways
- Scope of RE43390 centers on methylnaltrexone for treating opioid-induced constipation, inclusive of various formulations and administration routes.
- Claims are broad but specific to certain compounds and uses, creating opportunities for competitors to design around these claims with alternative compounds.
- The current patent landscape is competitive, with several patents covering similar and improved treatments, emphasizing the importance of patent strength and possible licensing strategies.
- Market exclusivity remains strong until around 2028, after which generic or alternative treatments may accelerate market entry.
- Strategic patent filings in other jurisdictions and continued R&D are crucial to maintaining competitive advantage.
FAQs
Q1: Can a generic manufacturer produce methylnaltrexone formulations after 2028?
Yes. Once RE43390 expires around 2028, generic manufacturers may seek approval to produce and market methylnaltrexone-based treatments, provided no other patent barriers exist.
Q2: Are there patented alternatives to methylnaltrexone for opioid-induced constipation?
Yes. Patents like US 8,543,543 (naloxegol) and US 8,107,498 (naldemedine) cover alternative antagonists that can be used as substitutes.
Q3: What are potential challenges in challenging RE43390’s validity?
Challenges could include prior art demonstrating obviousness, insufficient disclosures, or invalidating references. The patent’s broad claims may face scrutiny if similar compounds and treatments were known before its priority date.
Q4: How does patent reissuance impact enforceability?
Reissue proceedings aim to correct or broaden claims, potentially extending patent scope but also opening avenues for validity challenges. The enforceability depends on maintaining patent validity through legal defenses.
Q5: Are combination therapies covered under RE43390?
Unless explicitly claimed, combination therapies with other drugs are not directly covered but could potentially be infringing if they involve methylnaltrexone treatments.
References
- US Patent RE43390, "Methods for treating constipation caused by opioid use," Progenics Pharmaceuticals, Inc., 2012.
- US Patent 7,910,590, Progenics Pharmaceuticals, Inc., 2011.
- FDA RELISTOR (methylnaltrexone bromide) approval documents.
- Patent landscape reports on opioid antagonists (2015-2023).
- World Intellectual Property Organization (WIPO) patent applications in pharmaceutical formulations.
More… ↓
⤷ Start Trial
|
